Information:
Fel:
ID
13588
Beskrivning
Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction; ODM derived from: https://clinicaltrials.gov/show/NCT02451774
Länk
https://clinicaltrials.gov/show/NCT02451774
Nyckelord
Versioner (1)
- 2016-02-18 2016-02-18 -
Uppladdad den
18 februari 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Lymphoblastic Leukemia NCT02451774
Eligibility Acute Lymphoblastic Leukemia NCT02451774
- StudyEvent: Eligibility
Similar models
Eligibility Acute Lymphoblastic Leukemia NCT02451774
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age and gender
Item
pediatric and teenaged patients of both genders ≤18 years of age with newly diagnosed acute lymphoblastic leukemia in accordance with french-american-british criteria and under immunophenotypical classification and paired within the risk-classification group.
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0079399 (UMLS CUI [2])
Body weight
Item
patients with ≥20 kg of weight at the time of treatment assignment.
boolean
C0005910 (UMLS CUI [1])
Compliance behavior
Item
patients who are able to swallow the medicine
boolean
C1321605 (UMLS CUI [1])
Informed consent
Item
patients agreeing to enter the protocol by the signing of informed consent by the parent
boolean
C0021430 (UMLS CUI [1])
Informed consent
Item
patients who could give their assent to enter the protocol
boolean
C0021430 (UMLS CUI [1])
Compliance behavior
Item
the parent or guardian must be able to read.
boolean
C1321605 (UMLS CUI [1])
C0586739 (UMLS CUI [2])
C0586739 (UMLS CUI [2])
Compliance behavior
Item
patients with treatment adherence of ≥80 percent
boolean
C1321605 (UMLS CUI [1])
Informed consent withdrawn
Item
patients or their parents who decide to abandon the study or who withdraw consent for participation
boolean
C0021430 (UMLS CUI [1])
Adverse events
Item
patients who present grade iii or higher adverse event.
boolean
C0877248 (UMLS CUI [1])
concomitant agent
Item
patients previously treated with chemotherapy and/or radiotherapy
boolean
C2347852 (UMLS CUI [1])
Comorbidity
Item
history of peptic acid disease or gastrointestinal bleeding
boolean
C0009488 (UMLS CUI [1])
Hypersensitivity
Item
known pentoxifylline intolerance and general intolerance to xanthine, caffeine or theophylline
boolean
C0020517 (UMLS CUI [1,1])
C0030899 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
C0043314 (UMLS CUI [1,4])
C0020517 (UMLS CUI [1,5])
C0006644 (UMLS CUI [1,6])
C0020517 (UMLS CUI [1,7])
C0039771 (UMLS CUI [1,8])
C0030899 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
C0043314 (UMLS CUI [1,4])
C0020517 (UMLS CUI [1,5])
C0006644 (UMLS CUI [1,6])
C0020517 (UMLS CUI [1,7])
C0039771 (UMLS CUI [1,8])
Concomitant agent
Item
patients in treatment with anticoagulants, cimetidine, ciprofloxacin, or theophylline
boolean
C2347852 (UMLS CUI [1])
Comorbidity down syndrome
Item
patients with down syndrome
boolean
C0013080 (UMLS CUI [1])
Comorbidity
Item
patients with several bleeding or extensive retinal hemorrhage, several cardiac arrhythmias (paroxysmal supraventricular tachycardia, congenital atrioventricular block, arrhythmias associated with congenital heart disease, digital poisoning, and patients after cardiac surgery, hypoxia, hypercapnia, and electrolyte disturbances)
boolean
C0009488 (UMLS CUI [1])
Comorbidity hypotension
Item
patients with hypotension
boolean
C0020649 (UMLS CUI [1])
liver failure
Item
several liver failures
boolean
C0085605 (UMLS CUI [1])
bleeding disorders
Item
bleeding diathesis (for bleeding disorders or anticoagulant medication)
boolean
C0005779 (UMLS CUI [1])